Colorectal carcinoma or cancer of the large bowel is one of the commonest cancers among humans, responsible for about 10% of all deaths caused by cancer in the western world.

It metastasises mainly to the liver and it is characteristic that 10-25% of patients already have hepatic metastases when the diagnosis is made, while 20-25% of patients are going to present hepatic metastases in the future. Life expectancy after a diagnosis of hepatic metastases is 6 months, if patients are left untreated. More than half of the patients with colorectal carcinoma die of hepatic metastases.

Transarterial chemoembolisation is an alternative method for the treatment of hepatic metastases in cases of colorectal cancer; it is accompanied by mild to medium toxicity and high response rates.

Relevant research has, indeed, shown that patients who can undergo repeated transarterial chemoembolisations enjoy more benefits in regard to their life expectancy.

Ioannis Dedes has been successfully performing chemoembolisations of hepatic metastases due to colorectal carcinoma for the last ten years.

Ask I. Dede, what can you expect from a treatment. Examines your personal file and discusses it with you

pic 26-3

Colorectal carcinoma (Cancer of the large bowel)